Nicola Gökbuget: GMALL Initial-1 Trial has been published in the Journal of Clinical Oncology
Nicola Gökbuget, Head of Clinical Trial Center at Goethe University Hospital, shared a post on LinkedIn:
“The German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia (GMALL) is happy to announce that the GMALL Initial-1 Trial has been published in the Journal of Clinical Oncology.
In this trial it was demonstrated that an innovative induction therapy with the CD22-directed conjugated antibody Inotuzumab Ozogamicin induces a high complete remission rate with limited toxicity in older patients with newly diagnosed Ph-negative B-Precursor ALL. Subsequent age-adapted standard chemotherapy was tolerated well leading to a favorable overall survival of 73% at 3 years. These results represent a considerable progress for the management of older patients with ALL and will be considered for planned subsequent GMALL treatment optimization trials.”
Source: Nicola Gökbuget/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023